Background Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are
associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-…

Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently
under evaluation in oncology clinical trials are largely not tumor selective. To be clinically …

A first-in-human clinical trial of ultrasmall inorganic hybrid nanoparticles, “C dots” (Cornell
dots), in patients with metastatic melanoma is described for the imaging of cancer. These …

In internal radionuclide therapy, a growing interest in voxel-level estimates of tissue-absorbed
dose has been driven by the desire to report radiobiologic quantities that account for the …

… The results we have presented are dependent on the choice of a T/B ratio of 1.2 to define
regions of tumor hypoxia. This threshold value was first proposed by Rajendran et al.(19) from …

Background The potential medical applications of nanomaterials are shaping the landscape
of the nanobiotechnology field and driving it forward. A key factor in determining the …

The reliability of radiation dose estimates in internal radionuclide therapy is directly related
to the accuracy of activity estimates obtained at each imaging time point. The recently …

Radioiodines, particularly 131 I, may be released into the environment in breach-of-containment
nuclear reactor accidents and localize in and irradiate the thyroid with an attendant risk …

In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of 89
Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)–targeted …

Internal dosimetry deals with the determination of the amount and the spatial and temporal
distribution of radiation energy deposited in tissue by radionuclideswithin the body. Nuclear …